Research progress on neonatal Fc receptors and their inhibitors in primary immune thrombocytopenia
Zhu Gengda
Fang Lijun
Yan Lixiang
Fan Chenyang
Sun Hui
Zhou Xinli
Zhang Yucheng
Shi Zhexin
Abstract：Primary Immune Thrombocytopenia(ITP)is an autoimmune disease mediated by platelet autoantibodies.Most ITP patients have antiplatelet antibodies against the immunoglobulin G(IgG)subtype,which interact with glycoproteins on platelets and megakaryocytes to increase platelet destruction and inhibit platelet production.Neonatal Fc receptor(FcRn)is used to maintain the homeostasis of IgG levels in the human body.Targeting FcRn by FcRn inhibitors can reduce pathogenic IgG in the blood,proving its efficacy in the treatment of ITP and other autoimmune diseases,and improving platelet counts in ITP patients to some extent.Both efgartigimod and Rozanolixizumab can bind to FcRn and lead to the reduction of circulating IgG.FcRn inhibitors can also indirectly prolong the half-life of romiplostim to improve the therapeutic effect.This review briefly summarizes the mechanism of inhibition of platelet destruction and production in ITP,the molecular mechanism of FcRn and FcRn inhibitors,the application of FcRn inhibitors in ITP,and the association of FcRn with romiplostim and intravenous Ig.
Keywords：Primary immune thrombocytopeniaNeonatal Fc receptorNeonatal Fc receptor inhibitorsImmunoglobulin G
Publication Date：2024-09-08
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：5( 1426-1430 )